68.72
price down icon0.10%   -0.07
after-market 시간 외 거래: 68.75 0.03 +0.04%
loading
전일 마감가:
$68.79
열려 있는:
$68.875
하루 거래량:
3.18M
Relative Volume:
0.71
시가총액:
$213.12B
수익:
$54.98B
순이익/손실:
$7.77B
주가수익비율:
27.60
EPS:
2.49
순현금흐름:
$9.14B
1주 성능:
-4.21%
1개월 성능:
-1.76%
6개월 성능:
+1.12%
1년 성능:
-12.69%
1일 변동 폭
Value
$68.61
$69.37
1주일 범위
Value
$68.61
$71.81
52주 변동 폭
Value
$61.24
$87.67

아스트라제네카 ADR Stock (AZN) Company Profile

Name
명칭
Astrazeneca PLC
Name
전화
44 20 3749 5000
Name
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
직원
61,100
Name
트위터
@AstraZeneca
Name
다음 수익 날짜
2024-11-12
Name
최신 SEC 제출 서류
Name
AZN's Discussions on Twitter

AZN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
68.72 222.43B 54.98B 7.77B 9.14B 2.49

아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-15 개시 Exane BNP Paribas Outperform
2025-02-13 업그레이드 UBS Neutral → Buy
2025-02-12 개시 Morgan Stanley Overweight
2024-11-20 업그레이드 UBS Sell → Neutral
2024-11-06 업그레이드 Deutsche Bank Sell → Hold
2024-09-13 다운그레이드 Deutsche Bank Hold → Sell
2024-05-30 개시 Goldman Buy
2024-04-16 업그레이드 Deutsche Bank Sell → Hold
2024-02-08 다운그레이드 Deutsche Bank Hold → Sell
2024-01-23 개시 Morgan Stanley Overweight
2024-01-16 재개 UBS Sell
2024-01-03 다운그레이드 Jefferies Buy → Hold
2023-12-18 개시 HSBC Securities Buy
2023-09-25 업그레이드 Jefferies Hold → Buy
2023-07-14 개시 HSBC Securities Buy
2023-07-12 업그레이드 UBS Neutral → Buy
2023-07-05 다운그레이드 Deutsche Bank Buy → Hold
2023-04-11 업그레이드 Morgan Stanley Equal-Weight → Overweight
2023-01-05 개시 BMO Capital Markets Outperform
2022-09-15 다운그레이드 Credit Suisse Outperform → Neutral
2022-09-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-08-29 업그레이드 Argus Hold → Buy
2022-06-14 다운그레이드 UBS Buy → Neutral
2022-02-11 업그레이드 DZ Bank Sell → Hold
2021-12-07 다운그레이드 Jefferies Buy → Hold
2021-08-12 재개 JP Morgan Overweight
2021-04-12 다운그레이드 Argus Buy → Hold
2021-03-16 업그레이드 Jefferies Hold → Buy
2021-02-25 업그레이드 UBS Neutral → Buy
2021-01-15 개시 Deutsche Bank Buy
2020-12-07 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-11-30 업그레이드 UBS Sell → Neutral
2020-11-11 업그레이드 HSBC Securities Reduce → Hold
2020-09-29 개시 Berenberg Buy
2019-11-22 개시 SVB Leerink Outperform
2019-10-25 업그레이드 Liberum Hold → Buy
2019-04-02 다운그레이드 UBS Neutral → Sell
2019-02-05 개시 Exane BNP Paribas Outperform
2019-01-25 업그레이드 Shore Capital Hold → Buy
2018-12-11 재개 Jefferies Hold
2018-10-09 개시 Guggenheim Buy
2018-08-16 다운그레이드 Jefferies Buy → Hold
2018-03-19 업그레이드 Jefferies Hold → Buy
2018-02-06 재확인 Leerink Partners Mkt Perform
2018-02-05 재확인 Bernstein Outperform
2018-01-18 재확인 Leerink Partners Mkt Perform
2017-12-29 업그레이드 JP Morgan Neutral → Overweight
2017-10-16 업그레이드 Credit Suisse Neutral → Outperform
2017-09-25 업그레이드 Exane BNP Paribas Neutral → Outperform
2017-09-22 업그레이드 Bernstein Mkt Perform → Outperform
모두보기

아스트라제네카 ADR 주식(AZN)의 최신 뉴스

pulisher
12:09 PM

AstraZeneca’s Observational SLE Study in Kazakhstan: Key Insights for Investors - TipRanks

12:09 PM
pulisher
12:08 PM

AstraZeneca’s Promising Pediatric SLE Study: Anifrolumab’s Potential Impact - TipRanks

12:08 PM
pulisher
12:07 PM

What analysts say about AstraZeneca PLC Depositary Receipt stockConsistent triple returns - Autocar Professional

12:07 PM
pulisher
12:06 PM

AstraZeneca’s New Phase II Study: A Potential Breakthrough in Liver Cancer Treatment - TipRanks

12:06 PM
pulisher
12:03 PM

AstraZeneca’s COPD Study: Potential Game-Changer for Cardiopulmonary Outcomes - TipRanks

12:03 PM
pulisher
12:01 PM

AstraZeneca’s AIRSUPRA Study: A Potential Game-Changer in Asthma Treatment - TipRanks

12:01 PM
pulisher
11:02 AM

AstraZeneca reports positive results from Tagrisso combo trial - Seeking Alpha

11:02 AM
pulisher
07:06 AM

AstraZeneca’s lung cancer drug shows improved survival with chemotherapy combo - Investing.com UK

07:06 AM
pulisher
04:55 AM

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. (TEM) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.

04:55 AM
pulisher
04:50 AM

Is it worth me buying more AstraZeneca shares at just over £13? - Yahoo.co

04:50 AM
pulisher
Jul 20, 2025

What drives AstraZeneca PLC Depositary Receipt stock priceBreakthrough profit margins - PrintWeekIndia

Jul 20, 2025
pulisher
Jul 20, 2025

Is AstraZeneca PLC Depositary Receipt a good long term investmentUnrivaled growth potential - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 20, 2025

AstraZeneca PLC Depositary Receipt Stock Analysis and ForecastHigh-performance investment picks - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

Is AstraZeneca (AZN) a Reliable Dividend Stock for Long-Term Investors? - yahoo.co

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s Latest Study on Dato-DXd for NSCLC: Key Insights for Investors - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s CASPIAN Study: A Promising Update in Lung Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s Benralizumab Study: Real-World Insights for Severe Asthma - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s PRIMULA Lac Study: A Key Step in Anifrolumab’s Market Journey - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s Ravulizumab Study: A Potential Game-Changer for gMG Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s Anifrolumab Study: A Potential Game-Changer for SLE Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s Pediatric Hyperkalaemia Study: A Potential Game-Changer - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s AQUALIS Study: Enhancing CLL Patient Quality of Life with Acalabrutinib - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s DESTINY-Endometrial01 Study: A New Hope for Endometrial Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s REBECCA Study: Real-World Insights into Early Breast Cancer Management - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s Moxetumomab Pasudotox Safety Study Terminated: Market Implications - TipRanks

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies - MSN

Jul 18, 2025
pulisher
Jul 18, 2025

AstraZeneca’s Promising Study on Endometrial Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 17, 2025

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com

Jul 17, 2025
pulisher
Jul 17, 2025

Contact Levi & Korsinsky by February 21, 2025 Deadline to Join Class Action Against AstraZeneca PLC(AZN) - MarketScreener

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s New Study Sheds Light on COPD Burden in Egypt - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s INTERSTELLAR Study: Real-World Insights into Anifrolumab for Lupus - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca and Bayer’s Collaborative Study on Metastatic Prostate Cancer: A Potential Game-Changer? - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s DAISY Study: A New Hope for Systemic Sclerosis Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s OPTIMISE-CKD Study: A Closer Look at Chronic Kidney Disease Management in Spain - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s Real-Life Study on Benralizumab: Market Implications and Progress - The Globe and Mail

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s AI-Driven Breast Cancer Risk Study: A New Frontier in Personalized Medicine - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s Dapagliflozin Study: A New Hope for Chronic Kidney Disease in China - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s New Phase III Study: A Potential Game-Changer in Biliary Tract Cancer Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s iCaReMe Global Registry: A Real-World Data Initiative - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca Completes Phase II Asthma Study: Market Implications and Insights - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca’s Phase III Study on Benralizumab: A Potential Game-Changer for Pediatric Asthma - TipRanks

Jul 17, 2025
pulisher
Jul 17, 2025

AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu - Seeking Alpha

Jul 17, 2025
pulisher
Jul 16, 2025

AstraZeneca Loses Bid To Revive Patent For Diabetes Drug - Law360

Jul 16, 2025
pulisher
Jul 16, 2025

JPMorgan Goes Global With HOLA ETF—Stocks Plus Built‑In Crash Protection - Benzinga

Jul 16, 2025
pulisher
Jul 16, 2025

AstraZeneca’s SERENA-6 Trial: A Potential Game-Changer in Breast Cancer Treatment - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

AstraZeneca’s New CAR T Therapy Study: A Potential Game-Changer for Refractory SLE - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

AstraZeneca’s Phase 3 COPD Study: Key Insights for Investors - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

AstraZeneca’s Promising Phase II Study on AZD7798 for Crohn’s Disease - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

AstraZeneca’s Benralizumab Trial: A Potential Game-Changer for Pediatric Eosinophilic Diseases - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

AstraZeneca’s New Study on AZD4954: A Potential Game Changer in Cardiovascular Treatment - TipRanks

Jul 16, 2025
pulisher
Jul 16, 2025

AstraZeneca’s Ravulizumab Study: A New Hope for gMG Patients - TipRanks

Jul 16, 2025

아스트라제네카 ADR (AZN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
자본화:     |  볼륨(24시간):